The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
p73 and p63 Are Homotetramers Capable of Weak Heterotypic Interactions with Each Other but Not with p53
Open accessAbstract
Mutations in the p53 tumor suppressor gene are the most frequent genetic alterations found in human cancers. Recent identification of two human homologues of p53 has raised the prospect of functional interactions between family members via a conserved oligomerization domain. Here we report in vitro and in vivo analysis of homo- and hetero-oligomerization of p53 and its homologues, p63 and p73. The oligomerization domains of p63 and p73 can independently fold into stable homotetramers, as previously observed for p53. However, the oligomerization domain of p53 does not associate with that of either p73 or p63, even when p53 is in 15-fold excess. On the other hand, the oligomerization domains of p63 and p73 are able to weakly associate with one another in vitro. In vivo co-transfection assays of the ability of p53 and its homologues to activate reporter genes showed that a DNA-binding mutant of p53 was not able to act in a dominant negative manner over wild-type p73 or p63 but that a p73 mutant could inhibit the activity of wild-type p63. These data suggest that mutant p53 in cancer cells will not interact with endogenous or exogenous p63 or p73 via their respective oligomerization domains. It also establishes that the multiple isoforms of p63 as well as those of p73 are capable of interacting via their common oligomerization domain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
p73 is a human p53-related protein that can induce apoptosis
Jost, C. A., Marin, M. C., & Jr, W. G. K. (1997) · Nature · doi:10.1038/38298 · Cited by 948
Cited by
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Role for the p53 homologue p73 in E2F-1-induced apoptosis
Irwin, M., Marin, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710
The p53/p63/p73 family of transcription factors: overlapping and distinct functions
Levrero, M., Laurenzi, V. D., Costanzo, A., Sabatini, S., Gong, J., Wang, J. Y. J., & Melino, G. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.10.1661 · Cited by 565
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., James, N., McGregor, J. M., Harwood, C. A., Yulug, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 515
p63 and p73: Roles in Development and Tumor Formation
Moll, U. M., & Slade, N. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.371.2.7 · Cited by 486
On the shoulders of giants: p63, p73 and the rise of p53
Yang, A., Kaghad, M., Caput, D., & McKeon, F. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(02)02595-7 · Cited by 486
Self-citationGaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis
Rocco, J. W., Leong, C.-O., Kuperwasser, N., DeYoung, M. P., & Ellisen, L. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.013 · Cited by 433
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
The Tumor Suppressor p53: From Structures to Drug Discovery
Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 357
Westfall, M. D., Mays, D. J., Sniezek, J. C., & Pietenpol, J. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.7.2264-2276.2003 · Cited by 330
Paleček, E., Tkáč, J., Bartošík, M., Bertók, T., Ostatná, V., & Paleček, J. (2015) · Chemical Reviews · doi:10.1021/cr500279h · Cited by 319
Dohn, M., Zhang, S., & Chen, X. (2001) · Oncogene · doi:10.1038/sj.onc.1204427 · Cited by 294
The role of tetramerization in p53 function
Chène, P. (2001) · Oncogene · doi:10.1038/sj.onc.1204373 · Cited by 271
p63 and p73 in human cancer: defining the network
DeYoung, M. P., & Ellisen, L. W. (2007) · Oncogene · doi:10.1038/sj.onc.1210337 · Cited by 266
Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222406899 · Cited by 210
Metadata
- Authors
- Davison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., & Arrowsmith, C. H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1999-06
- Volume
- 274
- Issue
- 26
- Pages
- 18709-18714
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2034010972
- Cited by
- 160
- References
- 4
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.